Piasecki returns to Torre Lazur McCann

After two years away, Marci Piasecki, a 10-year veteran of Torre Lazur McCann, has returned to the fold as president of the organization's East Hanover agency. She reports directly to Beverly Breitenbach, chief executive of US operations.
As head of Torre Lazur Communications, Piasecki will be in charge of overall operations, business development and strategic direction for accounts in a broad range of therapeutic categories.
During her two year hiatus, Piasecki was executive vice president and director of client services at Hyphen, a healthcare communications company owned by Omnicom.
Commenting on Piasecki's return, Breitenbach said, "We're thrilled to have Marci back, particularly as head of the East Hanover agency, where we are offering a hands-on approach for clients who prefer a smaller, more personal working environment." Clients of Torre Lazur Communications, she pointed out, will get the best of both worlds, combining the culture of a small agency with the resources of a large one.
"My return was both a personal and professional decision," said Piasecki. "Torre Lazur is 'home' to me. It provides the kind of strategic partnership--in terms of marketing and the client relationship--that I think an agency should provide. Being invited to help grow this up-and-coming agency within the parent organization was the icing on the cake," she added.
Piasecki originally joined Torre Lazur McCann in 1992 as senior account executive, primarily managing accounts in the oncology and vaccine franchises for GlaxoSmithKline.
You must be a registered member of MMM to post a comment.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.